Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...

Pluvicto is used to treat certain types of prostate cancer. It is a type of medicine called radioligand therapy. Common side effects include tiredness, dry mouth, nausea, decreased appetite, ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer. The Food and Drug ...

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include hormone-sensitive prostate cancer (HSPC). The new results come from the ...